Evaluation of the radiotherapy and/or therapeutical associations in prostate cancer using prostate specific antigen (PSA)

Novel statistics show that prostate cancer is the third mortality neoplasia type in man and reaches the first level after 75 years old. The disease appears without signal at initial stages of the prostate cancer, period at which it will be easily treated. The development of the prostate carcinoma in patients depends on the tumor histological degree, stage of the disease at the diagnostic time, tumoral mass, patient age and patient general health. The prostate specific antigen (PSA) is the tumor marker used to premature disease detection, stagement and patient monitoring after treatment. Distinct therapies or in association have been established, together with a premature diagnosis, to increase the patient survival, achieving the best health quality and disease heal. The applied gland dose and its profile are distinct between brachytherapy and teletherapy.The present paper describes several therapies applied to control the prostate tumors, standing radioactive implants (I125 ) and conventional radiotherapy. The goal of this paper is to show the different PSA levels resulting after radiation therapy, look upon tumor biology aspects, isodose profiles and serum PSA levels. (author)